Background Benign multiple sclerosis (MS), characterised by minimal disability despite long disease duration, remains poorly understood in terms of its determinants and prognostic implications. While ...

Sanofi to present new data from 14 abstracts across multiple sclerosis at ECTRIMS 2025 congress in Barcelona, Spain ...

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...